Kindstar Globalgene Technology, Inc. (9960.HK)

HKD 1.12

(0.0%)

Market Cap (In HKD)

1.05 Billion

Revenue (In HKD)

967.26 Million

Net Income (In HKD)

41.28 Million

Avg. Volume

539.5 Thousand

Currency
HKD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.93-1.79
PE
-
EPS
-
Beta Value
0.725
ISIN
KYG5262E1044
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Medical - Care Facilities
CEO
Dr. Shiang Huang
Employee Count
-
Website
https://www.kindstar.com.cn/en/
Ipo Date
2021-07-16
Details
Kindstar Global (Beijing) Technology, Inc. provides medical esoteric testing services to hospitals in China. Its services include medical research, drug trial, and translational medicine research services for physicians, medical science and technology institutions, specialty and general hospitals, and pharmaceutical companies. The company's lab platforms comprise flow cytometry, cytogenetic, medical genomics, molecular biology, hematopathology, mass spectrum, pathology, clinical immunology, microbiology, and scientific research laboratories. It provides tests in blood, tumor, and genetics; and cardiovascular, cerebrovascular, infectious, and autoimmune diseases, as well as in internal medicine, surgery, gynecology, pediatrics, and other specialties. The company was founded in 2003 and is headquartered in in Wuhan, China.